Sitemap - 2023 - The Sarcoma Letter

Sarcoma Cellular Therapeutics Initiative

Olaparib and Temozolomide

Trends in FDA Approvals for Sarcoma

Second Opinions

The Cisplatin Shortage

How I discuss treatment of desmoid tumors

Reflections on ASCO 2023

A few ASCO Abstracts

Imatinib Side Effects

Chemoimmunotherapy for Sarcoma

Diagnosis and Treatment of Conventional Chondrosarcoma

DOG1 in the Diagnosis of GIST

The Appointment

Dermatofibrosarcoma Protuberans

Avapritinib for PDGFRA D842V-Mutant GIST

Leiomyosarcoma Subtypes

Clear Cell Sarcoma

Regorafenib for Gastrointestinal Stromal Tumors

Malignant Peripheral Nerve Sheath Tumors

Trabectedin and Radiation

Basic Information about Clinical Trials

Undifferentiated Pleomorphic Sarcoma

Later Line therapies for patients with GIST

Sunitinib for Gastrointestinal Stromal Tumors

Grading in Soft Tissue Sarcomas

Cheaper Cancer Medications

Oral Treatment for Leiomyosarcoma

Giant Cell Tumor of Bone

Imatinib for Resected Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumors

Does ChatGPT know how to treat sarcoma?

What is a Sarcoma?

Surveillance of Sarcoma

Chemotherapy for Leiomyosarcoma

Treatment of Recurrent Ewing Sarcoma

Immunotherapy for Sarcoma

A New Diagnosis of Sarcoma

Controversies in the Management of Sarcoma Survey (Eur J Cancer 2023)

The 2ND-STEP Study

The DeFi Trial Review (Nirogacestat)

Remarks on Desmoid Tumors

About Osteosarcoma Management

Getting Started with Neoadjuvant treatment

A Letter to Patients and Providers

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts